Top
| Antidepressants | p. 2 |
| Selective Serotonin Reuptake Inhibitors (SSRI) | p. 3 |
| Norepinephrine Dopamine Reuptake Inhibitor (NDRI) | p. 13 |
| Selective Serotonin Norepinephrine Reuptake Inhibitor (SNRI) | p. 17 |
| Serotonin-2 Antagonists/Reuptake Inhibitors (SARI) | p. 20 |
| Noradrenergic/Specific Serotonergic Antidepressant (NaSSA) | p. 26 |
| Non-Selective Cyclic Antidepressants | p. 28 |
| Effects of Antidepressants on Neurotransmitters/Receptors | p. 37 |
| Pharmacological Effects of Antidepressants on Neurotransmitters/Receptors | p. 38 |
| Frequency of Adverse Reactions to Cyclic Antidepressants at Therapeutic Doses | p. 39 |
| Reversible Inhibitor of MAO-A (RIMA) | p. 41 |
| Irreversible Monoamine Oxidase Inhibitors | p. 44 |
| Frequency of Adverse Reactions to MAOI Antidepressants at Therapeutic Doses | p. 50 |
| Antidepressant Doses | p. 51 |
| Switching Antidepressants | p. 53 |
| Antidepressant Augmentation Strategies | p. 54 |
| Electroconvulsive Therapy (ECT) | p. 56 |
| Antipsychotics (Neuroleptics) | p. 61 |
| "Novel" Antipsychotics (Neuroleptics) | p. 69 |
| "Conventional" Antipsychotics (Neuroleptics) | p. 74 |
| Effects of Antipsychotics on Neurotransmitters/Receptors | p. 80 |
| Pharmacological Effects of Antipsychotics on Neurotransmitters/Receptors | p. 81 |
| Frequency of Adverse Reactions to Antipsychotics at Therapeutic Doses | p. 82 |
| Antipsychotic Doses | p. 84 |
| Comparison of Depot Antipsychotics | p. 87 |
| Extrapyramidal Side Effects of Antipsychotics | p. 89 |
| Switching Antipsychotics | p. 92 |
| Antipsychotic Augmentation Strategies | p. 93 |
| Antiparkinsonian Agents | p. 95 |
| Effects on Extrapyramidal Symptoms | p. 99 |
| Comparison of Antiparkinsonian Agents | p. 100 |
| Anxiolytic Agents | p. 102 |
| Benzodiazepines | p. 102 |
| Comparison of the Benzodiazepines | p. 109 |
| Buspirone | p. 114 |
| Hypnotics/Sedatives | p. 117 |
| Comparison of Hypnotics/Sedatives | p. 121 |
| Mood Stabilizers | p. 124 |
| Lithium | p. 124 |
| Carbamazepine | p. 131 |
| Valproate | p. 138 |
| Clonazepam | p. 143 |
| l-Tryptophan | p. 145 |
| Comparison of Mood Stabilizers | p. 147 |
| Psychostimulants | p. 149 |
| Comparison of Psychostimulants | p. 154 |
| Cognition Enhancers | p. 156 |
| Comparison of Acetylcholinesterase Inhibitors | p. 159 |
| Sex-Drive Depressants | p. 161 |
| Comparison of Sex-Drive Depressants | p. 162 |
| Drugs of Abuse | p. 164 |
| Alcohol | p. 166 |
| Hallucinogens | p. 169 |
| Stimulants | p. 173 |
| Opiates/Narcotics | p. 176 |
| Inhalants/Aerosols | p. 180 |
| Gamma Hydroxy Butyrate (GHB) | p. 181 |
| Treatment of Substance Use Disorders | p. 183 |
| Disulfiram | p. 183 |
| Naltrexone | p. 186 |
| Methadone | p. 188 |
| New Unapproved Treatments of Psychiatric Disorders | p. 190 |
| Adrenergic Agents | p. 192 |
| Calcium Channel Blockers | p. 194 |
| Cholinergic Agents | p. 195 |
| Dopaminergic Agents | p. 195 |
| GABA-Agents/Anticonvulsants | p. 196 |
| Peptides | p. 198 |
| Serotonergic Agents | p. 198 |
| Serotonin Antagonists | p. 199 |
| Steroid Biosynthesis Inhibitors | p. 200 |
| Miscellaneous | p. 200 |
| Herbal (Natural) Products | p. 203 |
| Glossary | p. 206 |
| Suggested Readings | p. 209 |
| Index of Drugs | p. 213 |
| Patient Information Sheets | p. 219 |
| Table of Contents provided by Syndetics. All Rights Reserved. |
